

Diethylenetriaminetriacetic acid 유도체와 Gd-DTPA와의 영상비교

Image Comparisons using a Diethylenetriaminetriacetic Acid Derivative and Gd-DTPA

조정근*, 이채호**, 한태종*, 임청환***, 김정남****, 최지원*****

전주대학교 방사선학과*, 원광대학교 생명나노화학부**, 한서대학교 방사선학과***,
경희의료원 방사선종양학과****, Symbion Imaging, Strathfield Private Hospital, Australia*****

Jung-Keun Cho(cjk0129@jj.ac.kr)*, Chai-Ho Lee(chaiho@wonkwang.ac.kr)**,
Tae-Jong Han(tjhan@jj.ac.kr)*, Cheong-Hwan Lim(lch116@hanseo.ac.kr)***,
Jung-Nam Kim(sohoza@khmc.or.kr)****, Ji Won Choi(medi30@yahoo.co.kr)*****

요약

본 연구는 상자성이며 중성자를 흡수하는 힘이 큰 gadolinium(III) 전이금속과 polyaminocarboxylic ligand를 합성하여 제조한 MRI 조영제와 현재 임상에서 널리 사용되고 있는 Gd-DTPA의 영상을 비교하였다. 1.0T(Harmony, SIEMENS) MR 장비를 이용하여 Saline 100cc에 Diethylenetriaminetriacetic acid 유도체와 Gd-DTPA를 각각 0.05mmol/L, 0.1mmol/L, 0.15mmol/L, 0.2mmol/L, 0.3mmol/L, 0.5mmol/L, 1mmol/L, 2mmol/L, 3mmol/L, 4 mmol/L로 희석한 팬텀을 영상화하였다. Head Coil을 사용하였으며, SE Pulse sequence와 영상변수는 TE를 14ms, 1NEX, matrix는 256×201로 고정하고, TR을 300ms, 400ms, 500ms, 600ms, 700ms, 800ms, 900ms, 1000ms, 1200ms, 1400ms, 1600ms로 변화하여 각 조영제의 농도와 TR의 변화에 따른 신호강도와 단순대조도비를 비교하였다. 측정된 자료는 통계패키지 프로그램인 SAS v8.1(GLM procedeur)을 사용하여 분석하였다. 조영제의 농도와 TR의 변화에 따른 영상의 신호강도를 비교한 결과 최대신호강도를 보인 1~2mmol/L에서 두 조영제간의 차이는 크지 않은 것으로 나타났다. 하지만 1mmol/L 이하의 낮은 농도에서는 Diethylenetriaminetriacetic acid 유도체의 신호강도가 현저히 높은 것을 알 수 있다. 단순대조도비를 비교한 결과에서도 신호강도와 같은 양상을 보였으며, 대체로 1mmol/L 이하의 낮은 농도에서는 Diethylenetriaminetriacetic acid 유도체가 Gd-DTPA에 비해 높은 대조도비를 보이고 그 이상의 농도에서는 Gd-DTPA의 대조도비가 높은 것으로 나타났다. 또한 TR에 따라 각각의 조영제 농도별 신호강도의 차이가 현저한 것으로 나타났다. 따라서 Gd-DTPA에 비해 Diethylenetriaminetriacetic acid 유도체의 효능이 뛰어나며, 조영제의 농도에 맞추어 적절한 TR을 사용하여 최적의 영상을 얻어야 할 것으로 사료된다.

■ 중심어 : | 과학기술 | 조영제 | 가돌리늄 | 신호강도 |

Abstract

In this study, image comparisons were carried out using a MRI contrast medium which was derived by mixing a polyaminocarboxylic ligand and a gadolinium (III) transition metal which is paramagnetic and has good neutron absorbing capabilities with Gd-DTPA which is currently being used widely in the clinical setting. By using a 1.0T (Harmony, SIEMENS) MR equipment, phantoms of which 100cc of saline was diluted with a diethylenetriaminetriacetic acid derivative and Gd-DTPA were imaged. The amount of diethylenetriaminetriacetic acid and Gd-DTPA which was diluted into the 100cc of saline was 0.05mmol/L, 0.1mmol/L, 0.15mmol/L, 0.2mmol/L, 0.3mmol/L, 0.5mmol/L, 1.0mmol/L, 2.0mmol/L, 3.0mmol/L and 4.9mmol/L respectively. Head coils were used and while fixing the SE pulse sequence and image variable (as TE is 14ms, 1NEX with a 256x201 matrix), the signal intensity and simple contrast ratios according to changing concentrations and TR were compared with various TR at 300ms, 400ms, 500ms, 600ms, 700ms, 800ms, 900ms, 1000ms, 1200ms, 1400ms and 1600ms. According to the comparison results of the signal intensity of the image based on changes in contrast medium concentrations and TR, the differences in signal intensity between the two contrast mediums were found to be small at 1.0~2.0mmol/L when the highest signal intensity was achieved. However, at concentrations of 1.0mmol/L or less, the signal intensity was markedly higher in the Diethylenetriaminetriacetic acid derivative than in the Gd-DTPA complex. It was also found that the differences in the signal intensities demonstrated by the concentrations of the contrast mediums were affected by the TR. Accordingly, the efficacy of the Diethylenetriaminetriacetic acid derivative was shown to be better than the Gd-DTPA and also possible to get the optimum image quality by the use of an appropriate TR with appropriate concentrations of contrast medium.

■ keyword : | Science Technology | Contrast Media | Gadolinium | Signal Intensity |

I. Introduction

Magnetic Resonance Imaging (MRI) is a powerful and non-invasive diagnostic technique useful in providing images of the inside of the human body. Gadolinium (III) complexes are used as magnetic resonance imaging contrast agents [1]. Contrast agents using paramagnetic metals such as gadolinium are routinely used in MRI to shorten longitudinal relaxation times (T1) of water protons and enhance image contrast. Because gadolinium allows up to nine coordinate sites, chelating moieties are typically octadentate with either acyclic or macrocyclic polyaminopolycarboxylate ligands that form kinetically and thermodynamically stable complexes with gadolinium. However, the gadolinium (III) ion is too toxic at the levels which are required in MRI and therefore cannot be injected intravenously. The currently used gadolinium (III) chelates are based on polyaminocarboxylate ligands [2]. The ligands for gadolinium complexes are polyaminepolycarboxylic acids such as diethylenetriaminepentacetic acid, 1, 4, 7, 10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and diethylenediaminetetra acid are among the chelating agents which have been used in such studies [3][4].

The use of intravenous contrast media for MRI procedures is a well-established clinical practice and investigations have been performed to assess the safety aspects of MRI contrast media. Numerous MRI contrast agents were developed in attempts to obtain higher quality images with resultant lowered toxicity by improving the characteristics and sensitivities of the contrast mediums [5-11].

In this study, image comparisons were carried out using MRI contrast mediums derived from mixing gadolinium (III) transition metals which is paramagnetic and has good neutron absorbing

capabilities with Gd-DTPA which is currently being used in the clinical setting.

II. Material & Method

1. Synthesis of Diethylenetriaminetriacetic acids




Fig. 1. Synthesis of Diethylenetriamine-N,N''-bis(N-benzylethylenediamide)-N,N',N''-triacetic acid




Fig. 2. Synthesis of Diethylene-triaminee N,N''-bis[(2-methylthio)ethylamide]-N',N''-triacetic acid




Fig. 3. Synthesis of [Diethylene-triamine-N,N''-bis(N-benzylethylenediamide)-N,N',N''-triacetato]gadolinium(III)




Fig. 4. Synthesis of [Diethylenetriamine-N,N''-bis[(2-methylthio)ethylamide]-N,N',N''-triacetato]gadolinium(III)

In formulating new ligands for gadolinium (III) complexes for potential MRI reagents, diethylenetriaminepentaacetic dianhydride and amine, N-benzylethylenediamine and 2-(methylthio)ethylamine were used to set the starting materials.

2. Image comparison between Diethylenetriaminetriacetic acid derivative and Gd-DTPA

By using a 1.0T (Harmony, SIEMENS) MR equipment, phantoms of which 100cc of saline was diluted using diethylenetriaminetriacetic acid and Gd-DTPA were imaged.

The amount of diethylenetriaminetriacetic acid and Gd-DTPA which was diluted into the 100cc of saline was 0.05mmol/L, 0.1mmol/L, 0.15mmol/L, 0.2mmol/L, 0.3mmol/L, 0.5mmol/L, 1.0mmol/L, 2.0mmol/L, 3.0mmol/L and 4.9mmol/L, respectively. Head coils were used and while fixing the SE pulse sequence and image variable (as TE is 14ms, 1NEX with a 256x201 matrix), the signal intensity and simple contrast ratios according to changing concentrations and TR were compared with various TR at 300ms, 400ms, 500ms, 600ms, 700ms, 800ms, 900ms, 1000ms, 1200ms, 1400ms and 1600ms.




Fig. 5. Image of Gd-DTPA according to density




Fig. 6. Image of Diethylenetriaminetriacetic acid derivative according to density

III. Results

The reaction of diethylenetriaminepentaacetic dianhydride with amine gave triacetic acid, diethylenetriamine- N,N'' -bis(N -benzylethylenediamide)- N,N',N'' -triacetic acid (Fig.1) and diethylenetriamine- N,N'' -bis[(2-methylthio)ethylamide]- N,N',N'' -triacetic acid [Fig. 2] with a 82~87% yield. The resultant ligand was reacted with gadolinium acetate in water at room temperature to give gadolinium complexes, [diethylenetriamine- N,N'' -bis(N -benzylethylenediamide)- N,N',N'' -triacetato] gadolinium (III) [Fig. 3] and [diethylenetriamine- N,N'' -bis[(2-methylthio)ethylamide]- N,N',N'' -triacetato] gadolinium (III) [Fig. 4] with a 82~87% yield.

According to the signal intensity comparison results [Fig. 5][Fig. 6], at the low concentrations of lower than 1.0mmol/L the signal intensity of the diethylenetriaminetriacetic acid was higher than that of the Gd-DTPA. However, at higher than 1.0mmol/L concentrations, the signal intensity of the Gd-DTPA was higher than that of the diethylenetriaminetriacetic acid derivative. The highest signal intensity was demonstrated at 3.0mmol/L with TR set at 300ms, 2.0mmol/L with TR set at 400 to 800ms and at 1.0mmol/L with TR set at 900 to 1600ms for the diethylenetriaminetriacetic acid. When Gd-DTPA was used, the highest signal intensity was achieved at 3.0mmol/L with TR set at 300ms, 2.0mmol/L with TR set at 400 to 1000ms and at 1.0mmol/L with TR set at 1200 to 1600ms [Fig. 7].

The simple contrast ratio comparison results also demonstrated similarities with the signal intensity comparison results. The simple contrast ratio was shown to be higher in the diethylenetriaminetriacetic acid derivative than in the Gd-DTPA at concentrations of lower than 1.0mmol/L while it was higher in the Gd-DTPA at concentrations greater

than 1.0mmol/L.





Fig. 7. Images and graphs of signal intensity according to repetition time(TR)

IV. Conclusion

According to comparison results of the signal intensities of the images based on the changes in the concentrations of the contrast medium and TR, the signal intensity differences between the contrast mediums was found to be relatively small at contrast medium concentrations of 1~2mmol/L where the highest signal intensities were demonstrated. However, at concentrations of lower than 1.0mmol/L, the signal intensity was markedly higher in the diethylenetriaminetriacetic acid derivative than in the Gd-DTPA. It was also found that the differences in signal intensities achieved using varying concentrations of contrast medium were also affected by the TR. By referring to the study which was

undertaken, it can be concluded that the efficacy of the diethylenetriaminetriacetic acid derivative is better than Gd-DTPA and it is also possible to obtain optimum image qualities by using an appropriate TR in relations to the varying concentrations of contrast medium diluted in saline solution.

참 고 문 헌

- [1] F. M. Cavagna, F. Maggioni, P. M. Casteli, M. Dapra, and V. Lurusso, "Gadolinium Chelates with Weak Binding to Serum Proteins: A New Class of High-Efficiency, General Purpose Contrast Agents for Magnetic Resonance Imaging," *Investigative Radiology*, Vol.32, No.12, pp.780-796, 1997.
- [2] P. Caravan, J. Ellison, T. J. McMurry, and R. B. Lauffer, "Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications," *Chemical Review*, Vol.99, No.9, pp.2293-2352, 1999.
- [3] L. Lattuada and G. Lux, "Synthesis of GD-DTPA-cholesterol: a new lipophilic gadolinium complex as a potential MRI contrast agent," *Tetrahedron Letters* Vol.44, pp.3893-3895, 2003.
- [4] (a) D. E. Reichert, S. J. Lewis, and C. J. Anderson, "Metal Complexes as Diagnostic Tools," *Coordination Chemistry Review*, Vol.184, No.1, pp.3-66, 1999.
(b) L. Thunus and R. Lejeune, "Overview of Transition Metal and Lanthanide Complexes as Diagnostic Tools," *Coordination Chemistry Review*, Vol.184, No.1, pp.125-155, 1999.
- [5] R. G. Cooper, C. J. Etheridge, L. Stewart, J. Marshall, S. Rudginsky, S. H. Cheng, and A. D. Miller, "Polyamine Analogues of β 3-[N-(N,N-Dimethylaminoethane)carbonyl]cholesterol (DC-Chol) as Agents for Gene Delivery," *Chemistry: A European Journal*, Vol.4, No.1, pp.137-151, 1998.
- [6] H. Vu, T. H. Schmalz, and K. Jayaraman, "Synthesis and Properties of Cholesteryl-Modified Triple-Helix Forming Oligonucleotides Containing a Triglycyl Linker," *Bioconjugate Chemistry*, Vol.5, pp.666-668, 1994.
- [7] (a) H. Ishiwata, A. Vertut-Doi, T. Hirose and K. Miyajima, "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," *Chemical & Pharmaceutical Bulletin*, Vol.43, No.6, pp.1005-1011, 1995.
(b) N. Boden, R. J. Bushby, S. Clarkson, S. D. Evans, P. F. Knowles, and A. Marsh, "The design and synthesis of simple molecular tethers for binding biomembranes to a gold surface," *Tetrahedron*, Vol.53, No.31, pp.10939-10952, 1997.
- [8] K. Akiyoshi, T. Nishikawa, S. Shichibe, and J. Sunamoto, "Stabilization of Insulin upon Supramolecular Complexation with Hydrophobized Polysaccharide Nanoparticle," *Chemistry Review*, Vol.24, No.8, p.707, 1995.
- [9] R. B. Lauffer and T. J. Brady, "Preparation and water relaxation properties of proteins labeled with paramagnetic metal chelates," *Magnetic Resonance Imaging*, Vol.3, No.1, pp.11-16, 1985.
- [10] (a) H. Paajanen, R. C. Brasch, U. Schmiedl, and M. Ogan, "Magnetic resonance imaging of local soft tissue inflammation using gadolinium-DTPA," *Acta Radiologica*, Vol.28, No.1, pp.79-83, 1987.
(b) R. X. Zhuo, Y. J. Fu, and J. Liao, "Synthesis,

- Relaxivity and Biodistribution of Novel Magnetic Resonance Imaging (MRI) Contrast Agents: Polylysine (Gd-DTPA/DOTA) with Pendent Galactose Moieties as Hepatocyte-targeting Groups," *Chinese Chemical Letters*, Vol.8, No.2, pp.157-160, 1997.
- [11] (a) D. L. Ladd, R. Hollister, X. Peng, D. Wei, G. Wu, D. Delecki, R. A. Snow, J. L. Toner, K. Kellar, J. Eck, V. C. Desai, G. Raymond, L. B. Kinter, T. S. Desser, and D. L. Rubin, "Polymeric Gadolinium Chelate Magnetic Resonance Imaging Contrast Agent Design, Synthesis, and Properties," *Bioconjugate Chemistry*, Vol.10, No.3, 1999.
- (b) W. Krause, N. Hackmann-Schlichter, F. K. Maier, and R. Müller, "Dendrimers in Diagnostic," *Topic in Current Chemistry*, Vol.210, pp.261-308, 2000.
- [12] (a) H. A. Goldstein, F. K. Kashanian, R. F. Blumetti, W. L. Holyoak, F. P. Hugo, and D. M. Blumenfeld, "Safety assessment of gadopentetate dimeglumine in U.S. clinical trials," *Radiology*, Vol.174, No.1, 1990.
- (b) G. Sze, M. Brant-Zawadzki, V. M. Haughton, K. R. Maravilla, M. T. McNamara, A. J. Kumar, A. M. Aisen, J. N. Dreibach, W. G. Bradley Jr, and J. C. Weinreb, "Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine," *Radiology*, Vol.181, No.3, pp.693-699, 1991.
- (c) V. M. Runge, W. G. Bradley, M. N. Brant-Zawadzki, M. J. Carvlin, D. N. DeSimone, B. L. Dean, W. P. Dillon, B. P. Drayer, A.E. Flanders, and S. E. Harms, "Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease," *Radiology*, Vol.181, No.3, pp.701-709, 1991.
- [13] T. J. Meade, A. K. Taylor, and S. R. Bullz, "New magnetic resonance contrast agents as biochemical reporters," *Current Opinion in Neurobiology*, Vol.13, No.5, pp.597-602, 2003.
- [14] GD(III)-Based Contrast Agents for MRI, Academic Press Pub, 2005.
- [15] Y. Tatsuhirom, I. Kenjiro, O. Keiji, A. Kohtaro, U. Toyokazu, H. Fuminori, M. Masaharu, S. Noboru, Y. Kengo, S. Hiroaki, U. Hideo, and K. Yoshiki, "In vivo MR detection of vascular endothelial injury using a new class of MRI contrast agent," *Bioorganic & Medicinal Chemistry Letters*, Vol.14, No.11, pp.2787-2790, 2004.
- [16] A. M. Prantner, V. Sharma, J. R. Garbow, and D. Piwnica-Worms, "Synthesis and Characterization of a Gd-DOTA-d-Permeation Peptide for Magnetic Resonance Relaxation Enhancement of Intracellular Targets," *Molecular Imaging*, Vol.2, No.4, pp.333-341, 2003.
- [17] B. A. Moffat, G. R. Reddy, P. McConville, D. E. Hall, T. L. Chenevert, R. R. Kopelman, M. Philbert, R. Weissleder, A. Rehemtulla, and B. D. Ross, "A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI," *Molecular Imaging*, Vol.2, No.4, pp.324-332, 2003.
- [18] E. C. Unger, D. K. Shen, and T. A. Fritz, "Status of liposomes as MR contrast agents," *Journal of Magnetic Resonance Imaging*, Vol.3, No.1, pp.195-198, 1993.
- [19] H. Tournier, R. Hyacinthe, and M. Schneider, "Gadolinium-Containing Mixed Micelle Formulations A New Class of Blood Pool MRI/MRA Contrast Agents," *Academic Radiology*, Vol.9, No.1, pp.S20-S28, 2002.
- [20] A. Scozzafava, L. Menabuoni, F. Mincione, G. Mincione, and C. T. Supuran, "Carbonic

anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties," Bioorganic Medicinal Chemistry Letters, Vol.11, No.4, pp.575-582, 2001.

[21] D. Shahbazi-Gahrouei, Williams, and B. J. Allen, "In vitro study of relationship between signal intensity and gadolinium-DTPA concentration at high magnetic field strength," Vol.45, pp.298-304, 2001.

[22] R. Frayne, B. G. Goodyear, P. Dichoff, M. L. Lanuzon, and R. J. Sevic, "Magnetic resonance imaging at 3.0 Tesla: challenges and advantages in clinical neurological imaging," Invest. Radiolol. Vol.38, pp.385-402, 2003.

저 자 소 개

조 정 근(Jung-Keun Cho)

종신회원



- 2004년 8월 : 한서대학교 방사선학과(이학석사)
- 2006년 3월 ~ 2007년 12월 : 원광대학교 화학과(박사수료)
- 2007년 3월 ~ 현재 : 전주대학교 방사선학과 교수

<관심분야> : 보건의료, 방사선

이 채 호(Chai-Ho Lee)

정회원



- 1977년 : 고려대학교 화학 학사
- 1982년 : 고려대학교 화학 석사
- 1986년 : 고려대학교 화학 박사
- 1987년 ~ 1990년 : University of Huston, Post-Doc
- 1982년 ~ 현재 : 원광대학교 생명나노화학부 교수

<관심분야> : 보건의료, 방사선의료

한 태 중(Tae-Jong Han)

정회원



- 1981년 : 고려대학교 물리학 석사
- 1987년 : 고려대학교 물리학 박사
- 1990년 ~ 1991년 : University of Toronto, Post-Doc
- 1984년 ~ 현재 : 전주대학교 방사선학과 교수

<관심분야> : 보건의료, 방사선의료

임 청 환(Cheong-Hwan Lim)

정회원



- 1997년 8월 : 단국대학교 보건행정학과(행정학석사)
- 2005년 2월 : 경원대학교 보건정보학과(보건학박사)
- 2001년 ~ 현재 : 한서대학교 방사선학과 교수

<관심분야> : 보건의료, 방사선

김 정 남(Jung-Nam Kim)

정회원



- 2004년 8월 : 경희대학교 경영대학원(경영학석사)
- 1995년 4월 ~ 현재 : 경희의료원 방사선종양학과

<관심분야> : 보건의료, 방사선

최 지 원(Ji Won Choi)

정회원



- 1998년 12월 : 호주, 시드니 대학교 진단방사선학(학사)
- 2004년 6월 : 미국, 로스앤젤레스 시티 칼리지 방사선학 수료(면허취득)
- 2006년 6월 : 호주, 시드니 대학교 의료방사선학(석사)

▪ 1998년 12월 ~ 현재 : 호주, 시드니, 스트라스필드 사립병원 진단방사선과 근무

<관심분야> : 보건의료, 방사선교육